FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

OMB APP	PROVAL
OMB Number:	3235-0076
Expires:	May 31, 2005
Estimated avera	age burden
hours per respo	

SEC USE ONLY							
Prefix	Serial						
DATER	ECEIVED						
J	1						

Name of Offering \(\bigsize \text{chec}	k if this is an amendment and name has changed, and ind	icate change)	
Kylin Therapeutics, Inc.	Series A-1 Convertible Preferred Stock Offering	reate change.)	
Filing Under (Check box(es)	that apply): \square Rule 504 \square Rule 505 \boxtimes Rule 506		ULOE PROCESSE
Type of Filing: ☑ New Fi	ling	= 5ccnon 4(0)	J OLOE
	A. BASIC IDENTIFICATION DAT	ra	- NUV 1.9 2007
1. Enter the information requ	uested about the issuer		THOMSON
	f this is an amendment and name has changed, and indica	te chango)	FINANCIAL
Kylin Therapeutics, Inc.	and make	te change.)	
Address of Executive Office	s (Number and Street, City, State, Zip Code)	Talanhana Numb	
	t Lafayette, Indiana 47906	(765) 412-6661	
Address of Principal Busines	ss Operations (Number and Street, City, State, Zip Code)	Telephone Numbe	- J. H.
(if different from Executive of	Offices) Same as above.	Same as above	
Brief Description of Busines			- 0,003090
Biotechnology company	focused on RNAi delivery devices and therapeu	ıtics	
T. CD.			
Type of Business Organization ✓ corporation			
business trust	☐ limited partnership, already formed ☐ limited partnership, to be formed	☐ other (please s	pecify):
Actual or Estimated Date of	Incorporation or Organization: 0 7 0 6	☑ Actual	☐ Estimated
Jurisdiction of Incorporation	or Organization: (Enter two-letter U.S. Postal Service abl	breviation for State:	
	CN for Canada; FN for other foreign jur	risdiction)	IN
GENERAL INSTRUCTIONS			

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq.

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where To File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION : Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENT	TIFICATION DATA		
2. Enter the information re	equested for the	following:			<u> </u>
• Each promoter of th	ne issuer, if the i	ssuer has been organize	ed within the past five year	arc.	
 Each beneficial own securities of the issu 	ner having the p	ower to vote or dispose,	or direct the vote or disp	osition of, 10%	or more of a class of equity
• Each executive office	er and director o	of cornorate issuers and o	f cornerate general and m		s of partnership issuers; and
• Each general and ma	anaging partner	of partnership issuers.	r corporate general and m	anaging pariner	's of partnership issuers; and
Check Box(es) that Apply:					
		☐ Beneficial Owne	r ⊠ Executive Officer	☑ Director	☐ General and/or Managing Partner
Full Name (Last name first	, if individual)				
J. Eric Davis			-		
Business or Residence Add			ip Code)	-	
3000 Kent Avenue, Wes					
Check Box(es) that Apply:		⊠ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first,	, if individual)				
Dr. Peixuan Guo					
Business or Residence Add			p Code)		
3125 Eden Avenue, Roc	om 1301, Cinc	innati, OH 45267			
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	☐ General and/or Managing Partner
Full Name (Last name first,	if individual)				
Christopher S. Meldrum					
Business or Residence Addr			p Code)		
2530 Meridian Parkway,	Suite 200, Di	urham, NC 27713			
Check Box(es) that Apply:	☐ Promoter	☑ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first,	if individual)			<u> </u>	
IN-vivo, LLC					
Business or Residence Addr	ess (Number an	d Street, City, State, Zij	Code)		
3000 Kent Avenue, Wes	t Lafayette, IN	1 47906			
Check Box(es) that Apply:	☐ Promoter	☑ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first,	if individual)			·	55 1 41 1101
Golden Pine Ventures, L	LC				
Business or Residence Addre	ess (Number an	d Street, City, State, Zir	Code)		
2530 Meridian Parkway,			,		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	☐ General and/or Managing Partner
Full Name (Last name first, i	if individual)		-		
J. Mark Braughler, Ph.D.	, ,				
Business or Residence Addre		d Street, City, State, Zin	Code)		
100 Technology Drive, S	uite 200, Rm	205, Pittsburgh, PA	15219		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	☐ General and/or
Full Name (Last name first, i	f individual)	<u> </u>			Managing Partner
Homer L. Pearce, Ph.D.	,				
Business or Residence Addre	ess (Number and	Street, City. State Zin	Code)		
84 Clifden Pond Road, Zi			2000)		
	///- 11 T				

				B. IN	FORMA'	TION AB	OUT OF	FERING					
Hasti	he issuer o	old order	es the iceu									Yes	
1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?											\boxtimes		
2. What	is the min	unum mv	esimeni in	at will be	accepted	rom any i	ndividuai'	?		••••••••			
3. Does	the offerin	g permit j	oint owne	rship of a	single uni	t?		•••••			• • • • • • • • • • • • • • • • • • • •	Yes ⊠	NO
4. Enter	the informa	ation reque	ested for ea	ach person	who has t	een or wil	l be paid o	r given, di	rectly or in	directly, an	ny commis	;-	
sion o	r similar re isted is an	muneratio	n for solici	itation of p	ourchasers	in connect	ion with s	ales of secu	irities in th	e offering	If a parcon	n	
list the	name of t	he broker	or dealer.	If more the	han five (5	or dealer ro o) persons	to be liste	wiin ine Si xd are asso	ciated per	with a stat	e or states h a broke	;, er	
or dea	ler, you ma	y set forth	the inforn	nation for t	that broker	or dealer	only.	2220	oluite per	oons or suc	a orone	1	
Full Name	(Last name	e first, if i	ndividual)	1									
					Not Ar	plicable							
Business or	Residence	e Address	(Number	and Street				-	_				
				_									
Name of A	ssociated E	Broker or I	Dealer		_		_		<u></u>				
							_						
States in W	hich Perso	n Listed F	las Solicit	ed or Inte	nds to Sol	icit Purcha	isers	-	<u> </u>				
[AL]	All States" [AK]	[AZ]											
[IL]	IN		[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]	
[MT]	[NE]	[NV]	NH		[NM]	[ME]	[MD]	[MA] [ND]	[MI]	MN	[MS]	[MO]	
RII	[SC]	[SD]	[NT]	[TX]	UT	VT	[VA]	[WA]	[OH]	[OK]	[OR]	[PA]	
Full Name ([VA]			[WI]	[WY]	[PR]	<u> </u>
i un ivanic (Last Hailie	i 111 St, 11 11	idividuai)										
Business or	Residence	Address	(Number :	and Street	City Stat	te Zin Co		_		 -			
		1 1 4 4 1 4 0 5	(1144,1100)	and Street	, City, Sta	ic, zip co	uc)						
Name of As	sociated B	roker or I	Dealer					-					
States in Wl	nich Person	n Listed H	las Solicite	ed or Inter	nds to Soli	cit Purcha	sers	_		<u>_</u>			
(Check "A	All States"	or check i	individual	States)	•••••	• • • • • • • • • • • • • • • • • • • •							States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]	
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]	
[MT]	[NE]	[NV]	[NH]	[NJ]		[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]	
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[[WA]]	[wv]	[WI]	[WY]	[PR]	
Full Name (Last name	first, if in	dividual)						-				
D	D '1	4.11	 _				<u>.</u>	<u></u>					
Business or	Residence	Address (Number a	ind Street,	City, Stat	e, Zip Coo	le)						
Name of Ass	enciated D	rokar ar D	Nan lau					_					
valle of As	sociated Di	oker or L	eater										
States in Wh	ich Person	Listed U	as Solioita	d or Inter-	da ta Sali	oie De 1		.					
(Check "A	Il States"	or check i	as soncite ndividual	su or inten States)	us to 50110	u Purcha						□ <u> </u>	
(Check "All States" or check individual States)													
[IL]	[[N]]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	MN	[MS]	[MO]	
[MI]	[NE]	[NV]	[NH]	[[IN]]	NM	[NY]	[NC]	[ND]	ЮН	[OK]	[OR]	[PA]	
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]	

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE	OF PROCEED	os
1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.		
	Type of Security	Aggregate Offering Price	Amount Alread Sold
	Debt	_	
	Equity		\$
	☐ Common ☑ Preferred	, , , , , , , , , , , , , , , , , , , ,	
	Convertible Securities (including warrants)	\$0	\$.0
	Partnership Interests		\$.0
	Other (Specify)		
	Total		\$
	Answer also in Appendix, Column 3, if filing under ULOE.	, , ,	
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		
		Number Investors	Aggregate Dollar Amour of Purchases
	Accredited Investors		\$.0
	Non-accredited Investors	0	\$ 0
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		
	Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		\$
	Regulation A		\$
	Rule 504		\$
1.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$ 0
	Printing and Engraving Costs	_	
	Legal Fees		\$ 5,000
	Accounting Fees.	_	\$ 30,000
	Engineering Fees	_	\$ <u>0</u>
	Sales Commissions (specify finders' fees separately)		\$ <u>0</u>
	Other Expenses (identify)		
			\$ 0

□ \$<u>0</u>

■ \$35,000

C. OFFERING PRICE, NUMBER	R OF INVESTORS, EXPENSES AND	USE OF PROCE	EDS
tion 1 and total expenses furnished in response to	o Part C - Question 4.a. This difference is	the	<u>\$ 1,465,000</u>
used for each of the purposes shown. If the amo estimate and check the box to the left of the estimate	ount for any purpose is not known, furnishate. The total of the payments listed must e	h an aual	
		Payments to Officers, Directors, & Affiliates	Payments To Others
Salaries and fees		□\$ [insert]	_ \$ [insert]_
Purchase of real estate		□\$ <u>0</u>	_ 🗆 🕻 0
Purchase, rental or leasing and iunstallation	n of machinery and equipment	□\$ 0	□\$ [insert]
Construction or leasing of plant buildings a	and facilities	□\$ 0	□\$ [insert]
offering that may be used in exchange for t	he assets or securities of another		
		□ <u>\$ 0</u>	□\$ <u>0</u>
		□ <u>\$ 0</u>	□\$ [insert]
		□\$ <u>0</u>	□\$ [insert]
Other (specify):		□\$ <u>0</u>	□\$ [insert]
		□\$ <u>0</u>	□\$ <u>0</u>
Column Totals		□\$ [total	□\$ [total]
Total Payments Listed (column totals added	d)	□ <u>\$ 1,</u>	465,000
D,	FEDERAL SIGNATURE		
wing signature constitutes an undertaking by the iss	suer to furnish to the U.S. Securities and I	Exchange Commiss	ion upon written re-
er (Print or Type)	Signature /	Date	
n Therapeutics, Inc.	1.7/	Octo	ber 31, 2007
	Title of Signer (Print or Type)		DOI 01, 2001
ric Davis	President and CEO		
S i	b. Enter the difference between the aggregate of tion 1 and total expenses furnished in response to "adjusted gross proceeds to the issuer."	b. Enter the difference between the aggregate offering price given in response to Part C - Q tion 1 and total expenses furnished in response to Part C - Question 4.a. This difference is "adjusted gross proceeds to the issuer." Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to used for each of the purposes shown. If the amount for any purpose is not known, furniss estimate and check the box to the left of the estimate. The total of the payments listed must e the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b about the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b about the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b about the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b about the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b about the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b about the adjusted gross proceeds to the issuer to a part C - Question 4.b about the adjusted gross proceeds to the issuer to any non-accretites involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger). Repayment of indebtedness. Working capital. Other (specify): Column Totals. Total Payments Listed (column totals added) D. FEDERAL SIGNATURE Tissuer has duly caused this notice to be signed by the undersigned duly authorized person. It owing signature constitutes an undertaking by the issuer to any non-accredited investor pursuant of its staff; the information furnished by the issuer to any non-accredited investor pursuant er (Print or Type) in Therapeutics, Inc. Title of Signer (Print or Type)	tion I and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above. Payments to Officers. Directors, & Affiliates Salaries and fees

-ATTENTION-----

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

	E. STATE SIGNATURE		
1.	Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule?	Yes	No ⊠
	See Appendix, Column 5, for state response.		
2	The undersigned issues however understance & Society Associated and the Control of the Control o		

OT ATE CLOSE ATURE

- 2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law. (N/A)
- 3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees. (N/A)
- 4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied. (N/A)

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type) Kylin Therapeutics, Inc.	Signature J. S./	Date October 31, 2007
Name (Print or Type) J. Eric Davis	Title (Print or Type) President and CEO	•

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX

1		2	3	· ·		4	-	_	5
	to non-a	to sell accredited is in State B-Item 1)	Type of security and aggregate offering price offered in State (Part C-Item1)		Type of investor and amount purchased in State (Part C-Item 2)				
State	Yes	No	Series A-1 Convertible Preferred Stock	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
AL				<u>.</u>		_			
AK	_			- u					
AZ				<u>-</u> .					
AR		<u></u>							
CA									
со									
СТ	-				<u> </u>			<u> </u>	
DE									
DC									-
_ FL		x	1,500,000	2	\$150,000	0	\$0		х
GA									
HI					<u> </u>				
ID									
IL									
IN		Х	1,500,000	6	\$400,000	0	\$0		Х
IA		_							
KS	_	<u>.</u> .							
KY	_								_
LA									
МЕ									
MD									
MA									
МІ									
MN									
MS									

APPENDIX

1	Ţ.	2	3	<u> </u>		4			5
	to non-a	I to sell ccredited s in State I-Item I)	Type of security and aggregate offering price offered in State (Part C-Item1)		amount purc	nvestor and hased in State -Item 2)		Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
State	Yes	No	Series A-1 Convertible Preferred Stock	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
МО						-	· ·		
MT									
NE									
NV									
NH			-,-						
NJ									
NM			.,						
NY									
NC									
ND		<u> </u>			<u> </u>				
ОН									
ОК				**	,				
OR							<u> </u>		
PA					71.00				
RI				-					
SC									
SD	į								
TN				<u>. </u>		<u> </u>		·	
TX	····								
UT_						-		· · ·	
VT						<u> </u>			
VA				. <u> </u>					
WA		-	1						
wv				<u> </u>					
WI			.,						

	DD			IV
А	rr	M.I	¥I,	ı a

1	2		3	4				5	
	Intend to sell to non-accredited investors in State (Part B-Item!)		Type of security and aggregate offering price offered in State (Part C-Item I)	Type of investor and amount purchased in State (Part C-Item 2)			Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)		
State WY	Yes	No	Series A-1 Convertible Preferred Stock	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
PR			_		· · · · · · · · · · · · · · · · · · ·		<u>-</u>	 	

